6533b7d4fe1ef96bd1262695

RESEARCH PRODUCT

742 EFFICACY AND SAFETY OF ENTECAVIR (ETV) PROPHYLAXIS IN INACTIVE HBV CARRIERS WHO UNDERWENT CHEMOTHERAPY FOR SOLID OR HAEMATOLOGICAL CANCER: INTERIM ANALYSIS OF A COHORT STUDY

subject

description

seroconversion rate at 48 weeks were 40.7% and 37% in PEG-IFN a-2a group, respectively, which are both higher than those in ETV group (16.7% and 13.3%, P all 0.05). The mean qHBsAg level in PEG-IFN a-2a group declined over time during treatment. The qHBsAg level at 48 weeks was significantly lower than that in ETV group ((2866.0±2580.4) vs (4335.8±2650.0) IU/mL, P = 0.027). A greater HBsAg decline was observed in HBeAg seroconverters compared with nonseroconverters. The decline from baseline was significantly different between seroconverters and non-seroconverters especially at 36 weeks ((1763.4±3116.2) vs (1333.5±2483.4) IU/mL, P = 0.036), and 48 weeks (1979.6±2897.1) vs (1631.8±2395.8) IU/mL, P = 0.01) as well. Although 11.1% of participants in PEG-IFN a-2a group developed HBVDNA relapse (>500 copies/mL) at 48 weeks, which did not occur in ETV group, there was no statistical difference between the two groups at virological relapse rate. Conclusion: For HBeAg-positive CHB patients who fail to achieve satisfactory endpoint with ETV therapy, sequential PEG-IFN a-2a treatment is an appropriate treatment option to achieve sustained immune control.